Cogstate Ltd ( (COGZF) ) has released its Q2 earnings. Here is a breakdown of the information Cogstate Ltd presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Cogstate Ltd is an Australian company specializing in the creation, validation, and commercialization of digital brain health assessments and quality assurance services for clinical trials. In its latest earnings report for the half-year ended December 31, 2024, Cogstate Ltd reported a significant increase in net profit before tax, reaching $5.2 million compared to $2.1 million in the previous corresponding period. The company’s Clinical Trials segment showed robust growth with a revenue increase of 27% to $22.7 million, while the Healthcare segment saw a decline in revenue due to amendments in the Eisai agreement. Cogstate’s operating revenue increased by 19% to $23.9 million, and basic earnings per share rose to 2.27 cents from 1.16 cents. Despite the decrease in contracted future revenue, Cogstate’s financial position remains solid with net assets of $44.3 million. Looking forward, Cogstate management focuses on leveraging decentralized clinical trial methodologies and expanding capabilities in key therapeutic areas to maintain growth momentum.
